60
Participants
Start Date
March 15, 2018
Primary Completion Date
February 29, 2020
Study Completion Date
April 11, 2022
Nivolumab
Nivolumab 240 mg given by intravenous infusion every 2 weeks
Cabiralizumab
Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
Urelumab
Urelumab 8 mg given by intravenous infusion every 4 weeks
Stereotactic Body Radiation Therapy
Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
University of Chicago Medical Center, Chicago
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of Chicago
OTHER